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Abstract
Background: Opportunistic infections due to Candida species occur frequently in cancer patients because of their
inherent immunosuppression. The aim of the present study was to investigate the epidemiology of yeast species
from the oral cavity of patients during treatment for oncological and haematological malignancies.
Methods: MALDI-TOF was performed to identify yeasts isolated from the oral cavity of 350 cancer patients. Moreover,
antifungal susceptibility testing was performed in according to CLSI guidelines (M27-A3).
Results: Among 162 yeasts and yeast-like fungi isolated from the oral cavity of cancer patients, Candida albicans
was the most common species (50.6%), followed by Candida glabrata (24.7%), Pichia kudriavzevii (Candida krusei
(9.9%)), Candida tropicalis (4.3%), Candida dubliniensis (3.7%), Kluyveromyces marxianus (Candida kefyr (3.7%)) and
Candida parapsilosis (1%). In addition, uncommon yeast species i.e., Saprochaete capitata, Saccharomyces cerevisiae,
Clavispora lusitaniae (C. lusitaniae) and Pichia kluyveri (C. eremophila) were recovered from oral lesions. Oral colonization
by C. albicans, non-albicans Candida species and uncommon yeasts were as follow; 55%, 44% and 1%, whereas oral
infection due to C. albicans was 33.3%, non-albicans Candida species 60.6%, and uncommon yeasts 6.1%. Poor oral
hygiene and xerostomia were identified as independent risk factors associated with oral yeast colonization. The overall
resistance to fluconazole was 11.7% (19/162). Low MIC values were observed for anidulafungin for all Candida and
uncommon yeast species.
Conclusions: This current study provides insight into the prevalence and susceptibility profiles of Candida species,
including emerging Candida species and uncommon yeasts, isolated from the oral cavity of Iranian cancer patients.
The incidence of oral candidiasis was higher amongst patients with hematological malignancies. The majority of oral
infections were caused by non-albicans Candida species which were often more resistant to anti-fungal agents. Our
findings suggest that anidulafungin should be used as antifungal of choice for prophylaxis in clinically high-risk patients
with documented oral colonization or infection.
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Background
Worldwide the incidence of mild to severe fungal infections
(FI) has dramatically increased in the last several decades,
especially in patients infected with human immunodefi-
ciency virus (HIV), those that prolongedly use broad-
spectrum antibiotics, patients undergoing hematopoietic
stem cell transplantation (HSCT), and those receiving
intensive chemo- and /or radiotherapy [1, 2]. The latter
factors are important, not only because of the cytotoxic
effects they have on mucosal immune defense mechanisms,
but also because they change the physiology and microbial
ecology of the oral environment to prolonged xerostomia
and hyposalivation leading to intra-oral colonization, thus
facilitating overgrowth of fungal pathogens leading to
significant patient morbidity [2, 3]. The most predominant
yeasts isolated from oral colonization and infection are
Candida species that are the most important opportunistic
fungal pathogens in humans and cause mucosal to deep-
seated candidiasis [4]. The incidence of oral colonization
and infection has been reported to be 43% to 90% and 13%
to 52% among cancer patients, respectively, and involves
the mouth cavity and surrounding soft tissue, followed by
pain, erythema, ulceration, quantitative and qualitative
salivary changes and taste disorders [5, 6]. Studies have
demonstrated that Candida albicans (78%) is predomin-
antly involved in oral mucositis. The species remains a
major source of illness during immunosuppression despite
the application of antifungal therapy and can cause a
systemic infection associated with significant morbidity and
mortality rates [3, 7]. Although C. albicans is responsible
for the vast majority of oral colonizations and infections,
non-albicans Candida species belong to diverse species
complexes, i.e., Candida parapsilosis, Candida glabrata,
Candida tropicalis, Kluyveromyces marxianus (Candida
kefyr), Pichia kudriavzevii (Candida krusei), Meyerozyma
guilliermondii (Candida guilliermondii) and other uncom-
mon yeast species with a reduced susceptibility to triazoles
and echinocandins become a serious clinical challenge and
thus the isolates need to be properly identified [8–12]. Little
is known about the etiological importance of yeasts in oral
colonization and infection among Iranian cancer patients.
Identification using DNA barcodes, is time consuming, ex-
pensive and sometimes unspecific for cryptic species.
Matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) is an important
technique for the rapid and reliable identification of species
with sufficient specificity, reproducibility and sensitivity [13,
14]. Herein, we investigated the prevalence of Candida
species and uncommon yeasts responsible for colonizing
and infecting the oral cavity of patients with different types
of cancer using MALDI-TOF MS for identification. More-
over, guidelines for the treatment of candidiasis have
approved the use of polyenes, azoles and echinocandins
[15, 16]. Notably, in recent years, highly elevated MICs to
antifungals, especially fluconazole, have appeared and
antifungal drug resistance is quickly becoming a serious
concern, especially when immunological defenses are
impeded. In vitro antifungal susceptibility tests have an
important role in surveillance of resistance and are also
beneficial for choosing the right antifungal agents to be
used for treatment. It seems that non-albicans Candida
strains show considerable emergence of resistance to anti-
fungal drugs [10, 17, 18]. Limited data on the in vitro anti-
fungal susceptibility patterns against isolates of Candida
species from the oral cavity of patients with oncological
and hematological malignancies are available. Therefore,
in vitro antifungal susceptibilities were determined against
162 clinically isolates of Candida species and uncommon
other yeast species from Iranian cancer patients.
Methods
This study was performed at the cancer center of the
Mazandaran University Hospital that has 1600 oncology
and hematology in-patient admissions per year. All
patients were required to sign an informed consent form
prior to entry into the study. During one year 350 oral
swab samples were randomly obtained from Iranian
cancer patients undergoing intensive chemotherapy,
namely 210 (60%) males and 140 (40%) females and ran-
ging 17–88 years in age with and without sign and
symptoms of oral infection, including white plaque,
erythematous and ulcerative lesions, dryness, pain,
altered taste sensation and halitosis. Demographic data
on age, gender, oral hygiene, type of cancer, history of
prior fungal infections, use of topical or systemic
antifungal therapy, prophylaxis and medications were
collected at enrolment.
Study design and clinical specimens
As oral examination, signs and symptoms of inflamma-
tion suggestive of oral candidiasis were documented
and included soreness, erythema, ulceration and the
presence or absence of white plaques in the mouth.
Specimens were obtained by sterile cotton swabs moist-
ened with normal saline that were placed on the
tongue, buccal mucosa and labial sulcus, transported in
sterile tubes and were examined initially in 10% KOH,
followed by inoculation on malt extract agar (MEA,
Difco) supplemented with chloramphenicol and
CHROMagar Candida medium (CHROMagar Com-
pany, Paris, France) to ensure purity, and incubated at
37 °C for 24 h. Strains were preliminarily identified
using conventional methods, i.e., germ tube tests, for-
mation of pseudohyphae, production of chlamydo-
spores and carbohydrate assimilation tests using the ID
32 C kit (bioMérieux, Marcy l’Etiole, France). Oral
yeast colonization was defined as presence of yeasts in
the oral cavity. Oral candidiasis was defined as presence
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of Candida species in the oral cavity together with
symptoms and signs of inflammation ⁄ mucositis and ⁄
or presence of white plaques.
Fungal species identification
Subsequently, genomic DNA was extracted from all test
isolates along with reference strains as described by Xu et
al. and stored at −80 °C prior to use [19]. All strains were
identified by PCR-RFLP and using the amplified HWP1
gene to distinguish members of the C. albicans complex
as previously described [20]. Cultures of Candida isolates
were preserved at −70 °C at the reference culture collec-
tion of invasive fungi research center (IFRC, Sari, Iran)
using cryo-tubes (Mast Diagnostics, Bootle, Merseyside,
UK) until further analysis.
MALDI-TOF MS-based identification of all yeast and
yeast-like isolates was performed according to Bruker
Daltonics (Bremen, Germany) with the ethanol (EtOH)/
formic acid (FA) extraction protocol. For extraction, two
loops of yeast biomass (1-μvolume, sterile inoculation
loop) not older than 24 h growing on Sabouraud Dextrose
Agar (SDA) were suspended in 300 μl of molecular graded
ionized water and further processed with 900 μl of 95%
EtOH. A volume of 25 μl of FA was found to be optimal
and an equal volume of acetonitrile (ACN) was added
later. From the crude protein extract of each tested strain,
1 μl was spotted onto steel target plate (Bruker Daltonics)
and allowed to dry at room temperature. Bacterial test
standard (Bruker Daltonics) was used as a positive control.
Before measurements, all tested spots were overlaid with
1 μl of alpha-cyano-4- hydroxycinnamic acid (Bruker
Daltonics) saturated matrix solution. The yeast identifica-
tion was operated by the MALDI Biotyper 3.0 system
based on mass spectra generated with the Microflex LT
software and compared with two databases simultan-
eously. Identification scores were interpreted according to
the manufacturer’s recommended criteria: a log score
value >2.0 indicated correct identification to the species
level, a log score 1.999 > value >1.7 correct genus recogni-
tion, and no reliable identification with a score < 1.7. Each
isolate was considered correctly identified if at least one of
the duplicates gained scores >2. Strains with results <2.0
or no peaks found were retested from a fresh culture. The
identification was also considered correct if at least one
spot from the duplicate gave a reliable identification with
score > 1.7 that was concordant with the sequencing
results [21, 22].
Antifungal susceptibility testing
Antifungal susceptibility testing was carried out using the
Clinical and Laboratory Standards Institute broth microdi-
lution method (CLSI), following the M27-A3 and M27-S4
guidelines [23, 24]. Amphotericin B (AMB; Sigma, St.
Louis, MO, USA), fluconazole (FLU; Pfizer, Groton, CT,
USA), caspofungin (CFG; Merck Sharp and Dohme BV,
Haarlem, The Netherlands) and anidulafungin (AFG;
Pfizer) were dissolved in 1% dimethyl sulfoxide (DMSO,
Sigma) and were prepared at a final concentration of
0.016–16 μg/ml for amphotericin B; 0.063–64 μg/ml for
fluconazole, and 0.008–8 μg/ml for caspofungin and anidu-
lafungin. RPMI 1640 medium with glutamine without
bicarbonate (Sigma) buffered to pH 7 with 0.165 mol/l 3-
N-morpholinepropanesulfonic acid (MOPS; Sigma) was
used. Drug-free and yeast-free controls were included, and
microtiter plates were incubated at 35 °C and read visually
after 24 h, as validated recently by Pfaller et al. [25, 26].
Pichia kudriavzevii (= C. krusei) ATCC 6258 and Candida
parapsilosis ATCC 22019 were used as quality control
strains. Except for amphotericin B, the MIC endpoints for
all antifungals were defined as the lowest drug concentra-
tion that caused 50% growth inhibition vis-à-vis the drug-
free controls. The MIC for amphotericin B was defined as
the lowest concentration at which there was 100% inhib-
ition of growth.
Statistical analysis
Statistical analyses were performed using SPSS (version
24.0; Windows, Chicago, IL, USA) and R Software (version
3.0.1). Binary and bayesian logistic regression were used to
model the effect of risk factors on colonization. P values of
<0.05 were considered statistically significant.
Results
Demographic, clinical information and types of cancers in
the study population are summarised in Table 1. In total,
we collected 162 (46.3%) strains of yeasts and yeast-like
fungi from 350 cancer patients undergoing intensive
chemotherapy. The mean age of the patients was 53 years
(range 17–88 years). Among the patients, males comprised
58.6% (95/162) and females 41.4% (67/162). Nearly half (n
= 83, 51.2%) of the patients suffered from different types of
lymphoma, 18 (11%) had colorectal cancer, 13 (8%) lung
cancer, 13 (8%) gastric cancer, 10 (6.2%) breast cancer, and
25 (15.4%) other solid tumors (i.e. liver, kidney, nasopha-
ryngeal, prostate, esophagus, cervical, uterus and ovaries
cancer). The age of the majority of cancer patients ranged
from 41 to 60 (51/162). A logistic regression analysis iden-
tified xerostomia and poor oral hygiene as independent risk
factors associated with oral yeast colonization (Table 2).
Oral yeast colonization was prevalent in 79.6% (129/162)
of all cancer patients and 20.4% (33/162) of those had clin-
ical and microbiological evidence of oral candidiasis. Type
of cancer and the number of chemotherapy sessions
showed a statistical significant risk for the development
oral infection. Figure 2 shows that increasing the number
of chemotherapy sessions of cancer patients, correlated
with the presence oral candidiasis. Oral yeast colonization
varied amongst different cancer types and was high in solid
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Table 1 Demographic and clinical description of Iranian cancer patients with oral colonization or infection
Cancer Type Count Candidiasis /
Colonization
Species Prophylaxis
Anamorph TeleomorphTotal (%) Sex (M/F)
Basal Cell Carcinoma 1 (0.6%) 0/1 0/1 C. albicans (1) Unknown 1
Breast Cancer 10 (6.1%) 0/10 3/7 C. albicans (9) - 1
C. krusei (1) Pichia kudriavzevii (1965)
Bronchial Adenoma 1 (0.6%) 1/0 0/1 C. albicans (1) – –
Congestive Heart
Failure
1 (0.6%) 0/1 0/1 C. albicans (1) – –
Colorectal Cancer 18 (11.1%) 9/9 3/15 C. albicans (7) - 1
C. glabrata (5) Unknown
C. kefyr (3) Kluyveromyces marxianus
(1971)
C. dubliniensis (2) Unknown
C. lusitaniae (1) Clavispora lusitaniae
Nasopharyngeal
Cancer
1 (0.6%) 1/0 1/0 C. albicans (1) – –
Esophagus Cancer 6 (3.7%) 2/4 0/6 C. glabrata (3) - –
C. albicans (2) -
C. krusei (1) Pichia kudriavzevii
(1965)
Gastric Cancer 13 (8.0%) 8/5 2/11 C. albicans (8) - 2
C. glabrata (2) -
C. dubliniensis (1) -
C. tropicalis (1) Unknown
Saprochata capitata (1) Unknown
Hepatocellular
Carcinoma
5 (3.1%) 2/3 1/4 C. albicans (3) - 1
C. glabrata (2) -
Renal Cell Carcinoma 1 (0.6%) 1/0 0/1 C. albicans (1) – –
Lung Carcinoma 13 (8.0%) 10/3 3/10 C. albicans (10) - –
C. glabrata (3) -
Lymphoma 83 (51.2%) 57/26 20/63 C. albicans (32) - 16
C. glabrata (22) -
C. krusei (14) Pichia kudriavzevii (1965)
C. tropicalis (6) -
C. dubliniensis (3) -
C. kefyr (3) Kluyveromyces marxianus
(1971)
C. eremophila (1) Pichia kluyveri
C. parapsilosis (1) Unknown
C. robusta (1) Saccharomyces cerevisiae
Nasopharyngeal
Cancer
2 (1.2%) 2/0 0/2 C. glabrata (2) – –
Pancreatic Cancer 1 (0.6%) 1/0 0/1 C. albicans (1) – –
Prostate Cancer 1 (0.6%) 1/0 0/1 C. albicans (1) – –
Sarcoma 1 (0.6%) 1/0 0/1 C. glabrata (1) – –
Uterine Cancer 4 (2.5%) 0/4 0/4 C. albicans (4) – –
Total 162 (≈100%) 95/67 33/129 C. albicans (82) - 22
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tumor patients (colonization rate 40.7%) compared with
patients with hematological malignancies (38.9%). Patients
with hematological malignancies had a higher rate of oral
infection (12.3%) than those with solid tumors (8%)
(Table 1). Figure 1 shows the results of identification based
on conventional and molecular tests and their concordance
at genus and species levels with MALDI-TOF assessments.
Conventional and molecular methods identified 144
isolates as C. albicans (n = 82), C. dubliniensis (n = 6), C.
glabrata (n = 40) and P. kudriavzevii (= C. krusei, n = 16).
The species distribution belonging to the oral colonization
was C. albicans (n = 71), C. dubliniensis (n = 4), C. glabrata
(n = 32), P. kudriavzevii (C. krusei) (n = 11) and unknown
species (n = 11). Overall C. albicans (n = 11), C. dublinien-
sis (n = 2), C. glabrata (n = 8), P. kudriavzevii (C. krusei) (n
= 5) and unknown species (n = 7) causes of oral candidiasis
were identified by conventional and molecular tests (Fig. 1).
Among the C. albicans complex, neither C. stellatoidea
nor C. africana were identified by HWP1 gene amplifica-
tion. Subsequently, all isolates and the remaining 18 un-
known isolates were identified and confirmed with
MALDI-TOF at the species level. Our data showed that
MALDI-TOF MS correctly identified 100% isolates with
score > 2.0, indicating a secure genus and species identifica-
tion. Isolates with scores of >2.0 comprised four genera
and 11 species. Among the 162 isolates, MALDI-TOF MS
identified 7 isolates (4.3% of all yeast isolates) as C. tropica-
lis, 6 (3.6% of all yeast isolates) as K. marxianus (= C. kefyr)
and 1 isolate as C. parapsilosis, which were not detected by
the conventional and PCR-RFLP based identification
methods. Overall C. glabrata (n = 40, 24.7%), followed by
P. kudriavzevii (C. krusei) (n = 16, 9.9%) were the most fre-
quent leading agent of non-albicans Candida species
among cancer patients. Overall 47.5% of patients (n = 77)
were colonized or infected by non-albicans Candida spe-
cies. In addition, MALDI-TOF MS identified (n = 4, 2.5%
of cancer patients) isolates as rarely uncommon yeasts, i.e.,
Saprochaete capitata, Saccharomyces cerevisiae, Clavispora
lusitaniae (= C. lusitaniae) and Pichia kluyveri (= C. ere-
mophila), which were not detected by the PCR-RFLP
method. Uncommon yeast species that colonized the oral
cavity of cancer patients were C. lusitaniae and S. cerevi-
siae, while S. capitata and P. kluyveri were found in oral
infection (Fig. 1). The majority of cancer patients were col-
onized or infected by a single yeast species, but 4.9% (n =
8) of patients had two different species present. Only pa-
tients who developed infection were given antifungal medi-
cations. Of these, 22 (13.6%) received prophylaxis with
fluconazole (200 mg/kg/d for 7–14 days) and if clinical
cure was not achieved in 14 days, the dose was increased
up to 400 mg/d. All these 22 patients had persistent can-
didiasis and were culture positive for Candida species (C.
albicans n = 7, P. kudriavzevii (C. krusei) n = 5, C. dubli-
niensis n = 3, C. glabrata n = 3, and one isolate of K. marx-
ianus (C. kefyr), C. tropicalis, S. capitata and P. kluyveri).
Antifungal susceptibility profiles
The in vitro susceptibility data and the MIC distribution
are presented in Tables 3 and 4. A total of 162 isolates
of Candida species and uncommon yeasts were analyzed
for their susceptibility to fluconazole, amphotericin B,
caspofungin and anidulafungin. Fluconazole exhibited
no activity against 15.9% (n = 13) of C. albicans isolates
(MIC of 16 to >64 μg/ml), whereas the remaining 69 iso-
lates revealed a MIC range of 0.063–8 μg/ml. Notably,
12.5% of C. glabrata isolates (n = 5) showed fluconazole
MICs of >64 μg/ml. All tested C. albicans isolates had
low MICs of amphotericin B (MIC50 values of 1 μg/ml)
but 35.4% (n = 29) of C. albicans isolates had markedly
elevated amphotericin B MICs ranging from 2 to 16 μg/
ml. Moreover, elevated geometric means (GM) were ob-
served for caspofungin (0.34 μg/ml) in comparison to
anidulafungin (0.06 μg/ml). Notably, 35% (n = 14) of the
C. glabrata, 15.9% (n = 13) of the C. albicans and 75%
(n = 12) of the P. kudriavzevii (C. krusei) isolates re-
vealed MICs of ≥1 μg/ml to caspofungin. Overall 27.8%
of Candida species and uncommon yeasts revealed
MICs of ≥1 μg/ml to caspofungin. All isolates showed
reduced MICs to anidulafungin with MICs ranging from
Table 1 Demographic and clinical description of Iranian cancer patients with oral colonization or infection (Continued)
Cancer Type Count Candidiasis /
Colonization
Species Prophylaxis
Anamorph TeleomorphTotal (%) Sex (M/F)
C. glabrata (40) -
C. krusei (16) Pichia kudriavzevii (1965)
C. tropicalis (7) -
C. dubliniensis (6) -
C. kefyr (6) Kluyveromyces marxianus
(1971)
Table 2 Logistic regression analysis of risk factors for oral yeast
colonization
Risk factors P-value Odds ratio 95% CI
Xerostomia 0.019 4.994 1.288–18.452
Poor oral
hygiene
0.014 2.734 1.207–6.261
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0.008 to 0.5 μg/ml, except four isolates of C. glabrata
that had a MIC of 1 μg/ml (Tables 3 and 4). Overall in
terms of GM MICs, anidulafungin demonstrated potent
activity against all isolates (n = 162), in comparison with
amphotericin B, caspofungin and fluconazole.
Discussion
Fungal infections caused by Candida species are common
in immunocompromised patients, and the incidence has
dramatically increased during the last decades [27, 28].
Several virulence factors contribute to the pathogenicity of
Candida yeasts, which is one of the main causes of
systemic infection in individuals with cancer and contrib-
ute to high mortality rates of these patients [29]. Previous
studies reported an incidence of oral yeast colonization
and infection amongst cancer patients, ranging from 43%
to 90% and 13% to 52%, respectively, depending greatly on
the type of cancer, regimens to manage the Candida infec-
tions, and advance of the disease [6]. In our study we have
investigated and compared the yeast colonization and in-
fection rate amongst Iranian cancer patient groups, namely
those with hematological malignancies and solid tumors
during chemotherapy, as well as their antifungal suscepti-
bilities. On sub-analysis of our study data, it becomes
apparent that there is a distinct difference in colonization
and infection rate and occurrence of yeast species amongst
different types of cancer and different chemotherapy
sessions (Table 1 and Fig. 2). The oral yeast colonization
rate was 79.6% and the incidence of oral infections (20.4%)
in our cancer population, which are similar to other
studies [6, 30]. Rautema et al. and Schelenz et al. observed
similar rates of oral candidiasis during radiotherapy treat-
ment, but this is much lower compared with previously re-
ported studies that reported rates of up to 58% [6, 31, 32].
It is well known that chemo-radiotherapy can lead to mu-
cositis, xerostomia and damage of the cell mediated im-
munity which plays an important role in the pathogenesis
of oral candidiasis and lead to promotes manifestation of
yeast infection [33, 34]. The oral colonization rate of our
hematology patients (38.9%) had little difference compared
with other studies in cancer patients (49.4% and 41%) [6,
32]. A low oral infection rate (8%) was seen in patients
with solid tumors although this group had somewhat
higher yeast colonization (40.7%). Patients with
hematological malignancies who generally undergo more
aggressive chemotherapy leading to a higher degree of
generalized immunosuppression, disruption of the
mucosal barrier have a subsequent increased risk of infec-
tion when compared with solid tumor patients, such as
those with prostate cancers. In this group of patients, it is
important to emphasize good oral hygiene and prevention
of infection. Our study showed that xerostomia and poor
oral hygiene are independent risk factors associated with
an increased risk of oral yeast colonization. Such associ-
ation has previously been described in hospitalized elderly
patients and is often accompanied with age, compromised
nutritional status, presence of dental prosthesis, hyposali-
vation, and terminal illness [4, 6, 35]. Several studies have
Fig. 1 Flow diagram for the identification of 162 yeast and yeast-like isolates. a Pichia kudriavzevii (Candida krusei). b Kluyveromyces marxianus
(Candida kefyr). c Pichia kluyveri (Candida eremophila)
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analyzed which Candida species were involved in
colonization and infection of cancer patients. A study in
Brazil showed that nearly half of the patients (42.9%) were
colonized by C. albicans and 33% of the patients by non-
albicans species (C. tropicalis, P. kudriavzevii (C. krusei)
and C. lusitanae) [36]. The prevalence of Candida species
in our study is similar to those mentioned in other reports
[37–39]. A recent study by Schelenz et al. reported the dis-
tribution of Candida species in 400 patients suffering from
hematological malignancies, head neck cancers and solid
tumors. These authors found C. albicans (74%) species
followed by C. glabrata (11.5%), C. tropicalis (2.6%), C.
krusei (2.6%) and C. parapsilosis (1.9%) to be involved [6].
Another study showed that approximately 85% (n = 50) of
cancer patients were positive for culture of Candida spe-
cies from the oral mucosa, with C. albicans being the most
prevalent species, followed by C. glabrata with 14.5% of
cancer patients [29]. Unlike other reports, the uncommon
species of S. capitata and P. kluyveri were found to be in-
volved in oral colonization and infection in the current
study (Table 1). Other species, including S. cerevisiae,
Debaryomyces hansenii (= C. famata) and Clavispora lusi-
taniae (= C. lusitaniae), have been previously isolated from
oral specimens, thereby acting as potential pathogens of
oral infection [6, 37]. Similar to other studies, the co-
isolation were seen in 4.9% (n = 8) of our cancer patients.
[6, 37]. Laboratories should be able to detect mixtures of
different yeast species in primary cultures because it is an
important issue for the management of oral candidiasis pa-
tients. In this study emerging species recovered from oral
cavity of cancer patients such as K. marxianus (C. kefyr),
C. parapsilosis, C. tropicalis and P. kudriavzevii (C. krusei)
Table 3 In vitro susceptibilities of 157 clinical isolates to four antifungal agents. MIC range, geometric mean, MIC50, and MIC90 values
are expressed in μg/ml
(No. of strains) Antifungal
agent
MIC μg/ml
MIC range MIC50 MIC90 GM MODE
All clinical strains
(n = 157)
Fluconazole 0.063–64 2 8 1.65 4
Amphotericin B 0.016–16 1 4 0.50 1
Caspofungin 0.008–8 0.5 mg/ml 2 μg/ml 0.34 0.5
Anidulafungin 0.008–1 0.063 0.5 0.06 0.063
C. albicans (n = 82) Fluconazole 0.063–64 0.5 8 0.80 0.5
Amphotericin B 0.016–16 1 4 0.62 1
Caspofungin 0.008–8 0.25 1 0.22 0.5
Anidulafungin 0.008–0.25 0.031 0.125 0.03 0.016
C. dubliniensis (n = 6) Fluconazole 0.063–0.125 0.125 0.125 0.11 0.125
Amphotericin B 0.016–2 0.031 2 0.09 0.031
Caspofungin 0.25–2 0.5 2 0.5 0.5
Anidulafungin 0.008–0.125 0.125 0.25 0.07 0.016
C. glabrata (n = 40) Fluconazole 0.25–64 8 64 7.08 4
Amphotericin B 0.016–4 1 2 0.62 1
Caspofungin 0.008–2 0.5 2 0.40 1
Anidulafungin 0.016–1 0.063 1 0.12 1
C. krusei (= Pichia kudriavzevii)
(n = 16)
Fluconazole 0.25–64 8 64 7.33 4
Amphotericin B 0.063–2 0.5 1 0.59 1
Caspofungin 0.063–4 2 4 1.13 1
Anidulafungin 0.016–0.25 0.125 0.25 0.07 0.25
C. tropicalis (n = 7) Fluconazole 0.063–8 4 8 0.63 0.063
Amphotericin B 0.031–2 1 2 0.39 2
Caspofungin 0.031–8 0.5 8 0.39 0.25
Anidulafungin 0.008–0.063 0.063 0.063 0.063 0.063
C. kefyr = (Kluyveromyces marxianus) (n = 6) Fluconazole 0.25–32 4 32 2.82 4
Amphotericin B 0.016–1 0.5 1 0.15 0.5
Caspofungin 0.125–0.05 0.25 0.5 0.25 0.125
Anidulafungin 0.031–0.063 0.063 0.5 0.04 0.063
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were misidentified by conventional methods. This finding
may be related to the fact that more reliable techniques
are rarely used to identify these species from clinical sam-
ples so far. Simple PCR-based analysis using amplicon
length differences has been used to identify closely related
Candida species in several studies [40]. Recent studies
described the use of MALDI-TOF mass spectrometry to
discriminate clinical samples [17, 41]. Accordingly, in this
study, the simultaneous use of PCR assays and MALDI-
TOF MS turned out to be a powerful technique for the ac-
curate identification of yeasts isolated from the oral cavity.
These findings are in accordance with recent studies
showing yeast identification rates of 97.6% by MALDI-
TOF MS [21, 42]. Similar to other studies, it seems that
the incidence of oral candidiasis in cancer patients showed
a shift towards non-albicans species probably due to
chemotherapy complications, the use of azoles as empir-
ical treatment, or azole prophylaxis [43]. Remarkably, the
emergence of non-albicans species was associated with re-
duced susceptibility to azole antifungal agents it compared
with these of common Candida species [18]. A serious
concern in cancer patients is that drug resistant isolates
may invade the deeper tissues leading to disseminated in-
fection. Therefore, according to the availability of limited
data on in vitro antifungal susceptibility values, determin-
ation of the antifungal resistance pattern is highly essential
before deciding on a specific treatment in order to choose
the proper antifungal drug and to predict the outcome of
therapy for routine periodic surveillance of fungal infec-
tions [11]. Fluconazole is the drug of choice for prophy-
laxis and treatment of severe candidiasis in cancer
patients, but prolonged use of this agent has contributed
to the development of drug resistance in Candida isolates
[44, 45]. The resistance rate for fluconazole in the present
study was 15.9% and 12.5% for C. albicans and C. glabrata,
respectively, which is in concordance with other studies
[37, 39, 46, 47]. A sub-analysis of our 162 isolates showed
that resistance to fluconazole was higher (11.7%) com-
pared with an UK-based study that indicated a lower re-
sistance rate for fluconazole (4.5%) [6]. All of the
uncommon yeasts were susceptible to fluconazole. In our
study, 39% of yeast strains from cancer patients exhibited
higher MIC values to amphotericin B, with MIC90 values
of 4 μg/ml. Regarding echinocandins, 27.8% of the
Candida isolates were resistant to caspofungin, while all
isolates, except C. glabrata (10%), were highly susceptible
to anidulafungin. Unfortunately, we did not have informa-
tion of recruited cancer patient prior to the initiation of
chemotherapy and/or radiotherapy. This could be seen as
a comparative data of the effect of chemotherapy and/or
radiotherapy on epidemiology of Candida spp.
Table 4 In vitro susceptibilities of rare clinical species (n = 1) to
four antifungal agents
Strains Antifungal agent MIC (μg/ml)
C. parapsilosis Fluconazole 0.25
Amphotericin B 0.125 μg/ml
Caspofungin 4
Anidulafungin 0.25
Pichia kluyveri
(Candida eremophila)
Fluconazole 0.5
Amphotericin B 1
Caspofungin 4
Anidulafungin 0.25
Clavispora lusitaniae
(Candida lusitaniae)
Fluconazole 0.5
Amphotericin B 0.016
Caspofungin 2
Anidulafungin 0.25
Saccharomyces
cerevisiae
Fluconazole 0.5
Amphotericin B 0.016
Caspofungin 4
Anidulafungin 0.25
Saprochaete capitata Fluconazole 1
Amphotericin B 4
Caspofungin 0.125
Anidulafungin 0.016
Fig. 2 Distribution of oral colonization and infection by C. albicans and non-albicans Candida among cancer individuals
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Conclusions
In conclusion, the results showed that non-albicans species
and uncommon yeasts are the most common yeast isolates
obtained from oral infections from Iranian cancer patients,
and C. glabrata and P. kudriavzevii (C. krusei) generally
predominate. Overall, the reasons for the emergence of the
rare yeast species are not clear, but some medical condi-
tions such as an increase of the number of chemotherapy
sessions, the use of azoles as empirical treatment or azole
prophylaxis may increase the risk of developing infection
caused by these uncommon yeasts. Furthermore, these
increases may also be attributed to improvement in the
diagnostic methodology e.g., use of MALDI-TOF MS,
making it possible to identify such uncommon yeast
species. Second, a significant proportion of isolates demon-
strated reduced susceptibility to currently used antifungal
agents. The study indicates that anidulafungin would be
the drug of choice in cancer patients undergoing intensive
chemotherapy with documented oral colonization or
candidiasis. However, the clinical effectiveness in the treat-
ment of infection and colonization remains to be
determined.
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